Home » Stocks » SLDB

Solid Biosciences Inc. (SLDB)

Stock Price: $6.48 USD 0.02 (0.31%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $6.50 +0.02 (0.31%) Jan 15, 7:09 PM
Market Cap 549.33M
Revenue (ttm) n/a
Net Income (ttm) -98.79M
Shares Out 48.30M
EPS (ttm) -2.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $6.48
Previous Close $6.46
Change ($) 0.02
Change (%) 0.31%
Day's Open 6.46
Day's Range 6.45 - 6.96
Day's Volume 845,764
52-Week Range 2.02 - 8.48

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
The Motley Fool - 1 week ago

Blame it on Sarepta.

GlobeNewsWire - 1 week ago

CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Du...

Benzinga - 1 month ago

Tv Therapeutics (NASDAQ: VTVT) shares were trading higher on Friday after the company said its Phase 2 Simplici-T1 study of TTP399 achieved the primary objective of a statistically significant...

Other stocks mentioned: VTVT, SLS
GlobeNewsWire - 1 month ago

CAMBRIDGE, Mass., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Du...

Zacks Investment Research - 1 month ago

Investors need to pay close attention to Solid Biosciences (SLDB) stock based on the movements in the options market lately.

Seeking Alpha - 2 months ago

SLDB is recovering from clinical holds placed on lead drug candidate SGT-001 for DMD. They entered a new deal with Ultragenyx, and have cash for the next year.

Seeking Alpha - 2 months ago

Solid Biosciences' (SLDB) CEO Ilan Ganot on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Solid Biosciences??? (SLDB) reports wider than expected loss in the third quarter of 2020.

GlobeNewsWire - 2 months ago

–IGNITE DMD clinical trial expected to resume dosing in the first quarter of 2021 –

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Du...

Zacks Investment Research - 2 months ago

Solid Biosciences (SLDB) will provide updates on its lead pipeline candidate,SGT-001, along with others when it releases third-quarter 2020 results.

Zacks Investment Research - 3 months ago

Investors need to pay close attention to Solid Biosciences (SLDB) stock based on the movements in the options market lately.

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Du...

24/7 Wall Street - 3 months ago

Solid Biosciences Inc. (NASDAQ: SLDB) shares more than doubled on Thursday after the company announced a key update from the U.S. Food and Drug Administration (FDA). Essentially, the agency ha...

GlobeNewsWire - 3 months ago

– Modifications to IGNITE DMD trial protocol and improvements to manufacturing processes enable continued program development –

PRNewsWire - 5 months ago

NEW YORK, July 29, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Solid Biosciences Inc. ("Solid Biosciences" or the "Company") (NASDAQ: SLDB).

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass., July 24, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy, ...

GlobeNewsWire - 6 months ago

CAMBRIDGE, Mass., June 18, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy, ...

Zacks Investment Research - 7 months ago

Solid Biosciences (SLDB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research - 8 months ago

Top Ranked Momentum Stocks to Buy for May 13th

Other stocks mentioned: IDCC, ISEE, MRSN
GlobeNewsWire - 8 months ago

CAMBRIDGE, Mass., May 07, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy, a...

InvestorPlace - 8 months ago

RBC Capital has peered into its crystal ball to reveal some of the market's most exciting biotech stocks. Here are seven that stand out.

Other stocks mentioned: ATRA, BHVN, CBAY, MRNS, PTCT, TBIO
GlobeNewsWire - 9 months ago

Smith to Deepen Strategic Leadership and Complement Commercial, Operational and Financial Expertise of the Board

The Motley Fool - 1 year ago

The company announced plans to slash its head count and go all in on a single gene therapy. Is that wise or stubborn?

GlobeNewsWire - 1 year ago

CAMBRIDGE, Mass., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) today announced changes to its organizational structure to create a leaner company focused on advanc...

The Motley Fool - 1 year ago

Early data for its side-effect-ridden gene therapy SGT-001 doesn't look very promising.

24/7 Wall Street - 1 year ago

Solid Biosciences Inc. (NASDAQ: SLDB) shares jumped on Wednesday after the firm provided an update from its midstage study in Duchenne muscular dystrophy (DMD).

Benzinga - 1 year ago

Solid Biosciences Inc (NASDAQ: SLDB) shares are advancing strongly Wednesday following on an update on its clinical development program for its SGT-001, its gene transfer investigational candi...

Market Watch - 1 year ago

Shares of Solid Biosciences Inc. SLDB, +7.99% gained 22% in premarket trading on Wednesday after the company said two patients who received doses of its experimental Duchenne muscular dystroph...

GlobeNewsWire - 1 year ago

- Demonstrated expression of SGT-001 microdystrophin and nNOS function provide evidence that SGT-001 has the potential to provide therapeutic benefit for patients with Duchenne

Zacks Investment Research - 1 year ago

Investors need to pay close attention to Solid Biosciences (SLDB) stock based on the movements in the options market lately.

Seeking Alpha - 1 year ago

Solid Biosciences: Amid The Difficulty Is An Opportunity

The Motley Fool - 1 year ago

A clinical trial evaluating the company's lead drug candidate was placed on a clinical hold -- for the third time.

Benzinga - 1 year ago

Solid Biosciences Inc (NASDAQ: SLDB) shares pulled back to all-time lows Tuesday after the company said its lead gene therapy candidate to treat Duchenne muscular dystrophy has been placed on ...

GlobeNewsWire - 1 year ago

Company to hold conference call at 8:30 AM ET today Company to hold conference call at 8:30 AM ET today

InvestorPlace - 1 year ago

With the markets at all-time highs, no one is thinking about stocks to sell. And that’s one of the reasons why you should think exactly that.

Other stocks mentioned: CBL, FSLR, NIO, NLS, PIR, TSLA
The Motley Fool - 1 year ago

The clinical-stage biopharma announced changes to its lead pipeline program. Will it be enough?

The Motley Fool - 1 year ago

The gene therapy developer appears to be struggling to find a safe and effective dose of its experimental Duchenne muscular dystrophy treatment.

Zacks Investment Research - 1 year ago

Gene therapy continues to be in focus given the recent spate of deals and acquisitions. We highlight four stocks, which have promising gene therapy candidates in their pipeline.

Other stocks mentioned: BOLD, QURE, RGNX
CNBC Television - 1 year ago

Final trades: Nielsen Holdings, Deere, Solid Biosciences, & Qualcomm

The "Halftime Report" traders give their top stocks to watch for the second half.

Other stocks mentioned: DE, NLSN, QCOM
CNBC Television - 1 year ago

Final Trades: Solid Biosciences

The "Halftime Report" traders give their top stocks to watch for the second half.

About SLDB

Solid Biosciences, a life science company, engages in developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to derive functional dystrophin protein expression in patients' muscles. Its portfolio also comprises Anti-LTBP4, a complementary disease modifying program that identifies and develops a monoclonal antibody intended to reduce fibrosis and inflammation by targeting and stabilizing the LTBP4 protein.... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Jan 26, 2018
CEO
Ilan Ganot
Employees
121
Stock Exchange
NASDAQ
Ticker Symbol
SLDB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for SLDB stock is "Hold." The 12-month stock price forecast is 6.70, which is an increase of 3.40% from the latest price.

Price Target
$6.70
(3.40% upside)
Analyst Consensus: Hold